Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CMPX NASDAQ:IMRX NASDAQ:MNPR NASDAQ:SCLX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCMPXCompass Therapeutics$1.83+1.1%$4.94$1.61▼$6.88$325.96M0.7916.18 million shs6.48 million shsIMRXImmuneering$5.22$5.33$1.10▼$10.08$337.72M0.37806,296 shs497,108 shsMNPRMonopar Therapeutics$63.58+1.8%$56.04$28.40▼$105.00$418.20M1.49161,665 shs183,343 shsSCLXScilex$7.82-2.7%$7.63$3.92▼$34.27$68.27M1.7795,488 shs112,534 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCMPXCompass Therapeutics-1.90%+2.26%-65.91%-72.24%+2.84%IMRXImmuneering+0.58%-0.38%-0.19%+5.88%+369.00%MNPRMonopar Therapeutics-2.24%+19.71%+16.45%+8.10%+62.60%SCLXScilex-15.37%-23.57%+14.53%-5.30%+74.59%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCMPXCompass Therapeutics$1.83+1.1%$4.94$1.61▼$6.88$325.96M0.7916.18 million shs6.48 million shsIMRXImmuneering$5.22$5.33$1.10▼$10.08$337.72M0.37806,296 shs497,108 shsMNPRMonopar Therapeutics$63.58+1.8%$56.04$28.40▼$105.00$418.20M1.49161,665 shs183,343 shsSCLXScilex$7.82-2.7%$7.63$3.92▼$34.27$68.27M1.7795,488 shs112,534 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCMPXCompass Therapeutics-1.90%+2.26%-65.91%-72.24%+2.84%IMRXImmuneering+0.58%-0.38%-0.19%+5.88%+369.00%MNPRMonopar Therapeutics-2.24%+19.71%+16.45%+8.10%+62.60%SCLXScilex-15.37%-23.57%+14.53%-5.30%+74.59%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCMPXCompass Therapeutics 2.86Moderate Buy$13.60643.17% UpsideIMRXImmuneering 2.86Moderate Buy$16.50216.09% UpsideMNPRMonopar Therapeutics 3.00Buy$107.0068.29% UpsideSCLXScilex 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest SCLX, MNPR, CMPX, and IMRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/28/2026CMPXCompass Therapeutics Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOutperform ➝ Market Perform4/28/2026CMPXCompass Therapeutics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$13.00 ➝ $7.004/28/2026CMPXCompass Therapeutics Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform$10.004/27/2026CMPXCompass Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$24.004/27/2026CMPXCompass Therapeutics D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$30.004/21/2026MNPRMonopar Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026CMPXCompass Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/30/2026MNPRMonopar Therapeutics Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$100.003/27/2026IMRXImmuneering Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/24/2026CMPXCompass Therapeutics GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$12.003/12/2026CMPXCompass Therapeutics Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight(Data available from 5/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCMPXCompass Therapeutics$850K387.72N/AN/A$1.04 per share1.76IMRXImmuneeringN/AN/AN/AN/A$3.38 per shareN/AMNPRMonopar TherapeuticsN/AN/AN/AN/A$20.62 per shareN/ASCLXScilex$30.25M2.19N/AN/A($24.94) per share-0.31Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCMPXCompass Therapeutics-$66.49M-$0.41N/AN/AN/AN/A-39.75%-35.29%5/14/2026 (Estimated)IMRXImmuneering-$56.03M-$1.38N/AN/AN/AN/A-43.33%-39.75%5/11/2026 (Estimated)MNPRMonopar Therapeutics-$13.72M-$1.82N/AN/AN/AN/A-14.24%-13.93%5/12/2026 (Estimated)SCLXScilex-$358.73M-$36.45N/AN/AN/A-1,185.78%N/A-178.57%6/3/2026 (Estimated)Latest SCLX, MNPR, CMPX, and IMRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/3/2026N/ASCLXScilex-$0.3373N/AN/AN/A$15.00 millionN/A5/14/2026Q1 2026CMPXCompass Therapeutics-$0.10N/AN/AN/A($0.82) millionN/A5/12/2026Q1 2026MNPRMonopar Therapeutics-$0.8975N/AN/AN/AN/AN/A5/11/2026Q1 2026IMRXImmuneering-$0.30N/AN/AN/AN/AN/A5/5/2026Q1 2026CMPXCompass Therapeutics-$0.10-$0.10N/A-$0.10($0.82) millionN/A4/10/2026Q4 2025SCLXScilex-$0.47-$4.60-$4.13-$4.60$12.10 million$4.79 million3/27/2026Q4 2025MNPRMonopar Therapeutics-$0.5123-$0.61-$0.0977-$0.61N/AN/A3/6/2026Q4 2025IMRXImmuneering-$0.31-$0.18+$0.13-$0.18N/AN/A3/5/2026Q4 2025CMPXCompass Therapeutics-$0.10-$0.09+$0.01-$0.09($0.90) millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCMPXCompass TherapeuticsN/AN/AN/AN/AN/AIMRXImmuneeringN/AN/AN/AN/AN/AMNPRMonopar TherapeuticsN/AN/AN/AN/AN/ASCLXScilexN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCMPXCompass TherapeuticsN/A19.0415.02IMRXImmuneeringN/A17.5017.50MNPRMonopar TherapeuticsN/A51.3651.36SCLXScilexN/A0.080.07Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCMPXCompass Therapeutics68.43%IMRXImmuneering67.65%MNPRMonopar Therapeutics1.83%SCLXScilex69.67%Insider OwnershipCompanyInsider OwnershipCMPXCompass Therapeutics29.80%IMRXImmuneering22.90%MNPRMonopar Therapeutics20.50%SCLXScilex4.11%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCMPXCompass Therapeutics20180.09 million126.42 millionNot OptionableIMRXImmuneering6064.70 million49.88 millionNot OptionableMNPRMonopar Therapeutics106.70 million5.33 millionNot OptionableSCLXScilex808.49 million8.14 millionNo DataSCLX, MNPR, CMPX, and IMRX HeadlinesRecent News About These CompaniesPHOE stock more than doubles on strategic pivot into pharma industry with Scilex dealMay 5 at 8:01 PM | msn.comScilex Holding Company Announces Its Subsidiaries, ACEA Therapeutics, Inc. and ACEA Pharma, Inc., Entered into a Definitive Agreement with Phoenix Asia Holdings LimitedMay 5 at 3:00 PM | theglobeandmail.comScilex Subsidiary Reshapes Phoenix Asia via $1B Share DealMay 5 at 1:51 PM | tipranks.comScilex Holding Company Announces Acquisition Agreement Between ACEA Therapeutics and Phoenix Asia HoldingsMay 5 at 1:11 PM | quiverquant.comQScilex Holding Company Announces Its Board of Directors Approved May 26, 2026 as the Payment Date of the Previously Announced Dividend of Dream Bowl Meme Coin I Tokens to ...May 4, 2026 | markets.businessinsider.comScilex Holding Company Announces Its Board of Directors Approved May 26, 2026 as the Payment Date of the Previously Announced Dividend of Dream Bowl Meme Coin I Tokens to Record Holders of Common Stock and other Eligible Equity Securities as of the Record Date of April 30, 2026May 4, 2026 | globenewswire.comScilex Holding Company (NASDAQ:SCLX) Short Interest Down 15.4% in AprilMay 3, 2026 | americanbankingnews.comScilex (NASDAQ:SCLX) Downgraded to "Strong Sell" Rating by Wall Street ZenMay 2, 2026 | marketbeat.comShort Interest in Scilex Holding Company (NASDAQ:SCLX) Decreases By 15.4%May 1, 2026 | marketbeat.comScilex Plans Major Investment in Datavault Quantum-Ready NetworkApril 28, 2026 | tipranks.comDatavault AI (NASDAQ: DVLT) Executes $120M Term Sheet With Scilex for Quantum-Ready Edge Network DeploymentApril 27, 2026 | usatoday.comDatavault AI Announces Execution of Binding Term Sheet for $120 Million Cash Contribution From Scilex Holding Company to Fund 100-City GPU Expansion of Quantum-Ready SanQtum PlatformApril 27, 2026 | businesswire.comScilex Holding Company Announces Its Board of Directors Approved a Dividend of Dream Bowl I Meme Coin Tokens to Holders of Common Stock and other Eligible Equity Securities with a Record Date of April 30, 2026April 20, 2026 | globenewswire.comScilex (NASDAQ:SCLX) Announces Earnings ResultsApril 11, 2026 | marketbeat.comScilex Delays 2025 Annual 10-K FilingApril 1, 2026 | tipranks.comScilex Files Federal Lawsuit Over Misappropriated Datavault CollateralMarch 13, 2026 | tipranks.comScilex Holding Company Files Complaint Over Alleged Unauthorized Sale of $100 Million in Pledged SharesMarch 13, 2026 | quiverquant.comQScilex Holding Company Files Federal Securities Fraud Lawsuit Seeking Recovery of Approximately Ninety-Six (96) Million Misappropriated Collateral Shares of Datavault AI, Inc. from Marc Wade, The St. James Bank & Trust Company Ltd., Omega & Corinth Group Ltd.March 13, 2026 | globenewswire.comScilex Files Securities Fraud Suit Over Stock LoanMarch 13, 2026 | tipranks.comScilex Grants Oramed New Warrant in Financing AgreementFebruary 20, 2026 | tipranks.comDatavault AI Chief Executive Officer and President Issues Letter to Stockholders Highlighting 2025 Accomplishments and Outlook for 2026February 5, 2026 | accessnewswire.comANew MarketBeat Followers Over TimeMedia Sentiment Over TimeSCLX, MNPR, CMPX, and IMRX Company DescriptionsCompass Therapeutics NASDAQ:CMPX$1.83 +0.02 (+1.10%) Closing price 04:00 PM EasternExtended Trading$1.83 0.00 (-0.16%) As of 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.Immuneering NASDAQ:IMRX$5.22 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$5.20 -0.02 (-0.44%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.Monopar Therapeutics NASDAQ:MNPR$63.58 +1.15 (+1.84%) Closing price 04:00 PM EasternExtended Trading$63.58 +0.01 (+0.01%) As of 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.Scilex NASDAQ:SCLX$7.82 -0.22 (-2.74%) Closing price 04:00 PM EasternExtended Trading$7.86 +0.04 (+0.58%) As of 05:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company is also developing three product candidates, including SP-102 (10 mg dexamethasone sodium phosphate viscous gel) (SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a Phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4% (SP-103), a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a Phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules) (SP-104), a novel low-dose delayed-release naltrexone hydrochloride, which has completed Phase 1 trials for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SoundHound’s Bottom Is In—Inflection and 50% Upside Ahead? Rocket Lab Posts Record Q1 Revenue, Raises Q2 Guidance Hims & Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in Focus AppLovin Pops After Earnings With Growth Catalysts in Sight Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Why Lam Research Still Looks Like a Buy After a 300% Rally Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
